Assessment of safety and tolerability of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: Results of an open-label, randomized, multicenter, phase IIIB ESCAPE trial.

Aim: To assess the safety and tolerability of subcutaneous (SC) trastuzumab (Herceptin) administered either with a single-use injection device (SID) or manually from a vial using a hand-held syringe.

Methods: The ESCAPE trial (NCT02194166) included 90 women aged 18 years or older with HER2-positive early breast cancer who underwent surgical treatment and completed (neo) adjuvant chemotherapy and radiotherapy (if indicated). Patients enrolled in the study were first subjected to 4 cycles of trastuzumab IV (8 mg/kg loading dose followed by 6 mg/kg maintenance dose, q3w) prior to being randomized into groups: [A] SC trastuzumab (fixed dose 600 mg, q3w) administered through a hand-held syringe followed by 7 cycles of SC trastuzumab administered with an SID or [B] the reverse sequence.

CAR-T Cell Therapy for Classical Hodgkin Lymphoma.

Classical Hodgkin lymphoma (cHL) is a malignancy characterized by the presence of Hodgkin and Reed-Sternberg (HRS) cells within a complex tumor microenvironment (TME). Despite advances in conventional therapies, a subset of cHL patients experience relapse or refractory disease, necessitating the exploration of novel treatment strategies. Chimeric antigen receptor T cell (CAR-T cell) therapy has emerged as a promising approach for the management of cHL, harnessing the power of genetically modified T cells to recognize and eliminate tumor cells.

Second Primary Cancer Among Patients With Papillary Thyroid Carcinoma Following the Chernobyl Disaster.

Importance: To our knowledge, there are no complete population-based studies of the risks of developing second malignant tumors after papillary thyroid carcinoma (PTC) in patients following the Chernobyl nuclear accident.

Objective: To study the risk of second primary cancers in patients with PTC after the Chernobyl disaster.

Design, Setting, And Participants: This was a retrospective cohort study conducted in the Republic of Belarus over a 31-year time frame evaluating patients with primary PTC and second malignant tumors.

Adjuvant composite cold atmospheric plasma therapy increases antitumoral effect of doxorubicin hydrochloride.

Introduction: Cancer is a global health concern, with a significant impact on mortality rates. Despite advancements in targeted antitumor drugs, the development of new therapies remains challenging due to high costs and tumor resistance. The exploration of novel treatment approaches, such as combined chemotherapy, holds promise for improving the effectiveness of existing antitumor agents.

5-FU resistant colorectal cancer cells possess improved invasiveness and β-tubulin expression.

Background: Elevated β-tubulin levels are associated with resistance to a broad spectrum of drugs in different carcinomas and with poor prognosis of various epithelial cancers. 5-Fluorouracil (5-FU) is a widely used standard drug in chemotherapeutic regimens for colorectal cancer treatment, although the resistance to 5-FU is a major obstacle to successful therapy.

Aim: The aim of the study was to compare the invasive and adhesion properties and the expression levels of β-tubulin in a 5-fluorouracil (5-FU)-resistant colorectal cancer (CRC) cell line HCT116 and parental cells.

INTRAVASCULAR LIPOMA OF THE RIGHT BRACHIOCEPHALIC VEIN AND SUPERIOR VENA CAVA: A CASE REPORT AND LITERATURE REVIEW.

Lipomas of the major central veins are very rare tumors that have mostly been described in the inferior vena cava. They may be identified in as many as 0.5% of all CT scans.

Perspectives, fears and expectations of patients with gynaecological cancers during the COVID-19 pandemic: A Pan-European study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe).

Background: The impact of the COVID-19 pandemic on European gynaecological cancer patients under active treatment or follow-up has not been documented. We sought to capture the patient perceptions of the COVID-19 implications and the worldwide imposed treatment modifications.

Methods: A patient survey was conducted in 16 European countries, using a new COVID-19-related questionnaire, developed by ENGAGe and the Hospital Anxiety & Depression Scale questionnaire (HADS).

Efficacy of Adjuvant Systemic Chemotherapy Combined with Radical Surgery and Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer Treatment.

Evaluation of the efficacy of the combination of radical surgery, hyperthermic intraperitoneal chemotherapy (HIPEC), and adjuvant systemic chemotherapy (ACT) in reducing gastric cancer progression in patients with resectable serosa-invasive gastric cancer in a single institution. In 2015-2016, 19 patients with gastric cancer (stage IIB-IIIC) were included in the trial. The trial protocol comprised radical surgery, HIPEC (cisplatin 50 mg/m + doxorubicin 50 mg/m, 42 °C, 1 hour), and 1-8 cycles of ACT (oxaliplatin 100 mg/m administered on day 1 of each cycle and oral capecitabine 1000 mg/m (or tegafur 10-15 mg/kg) administered twice daily on days 1-14 of each cycle with an interval of 7 days between cycles).

Travel burden and clinical presentation of retinoblastoma: analysis of 1024 patients from 43 African countries and 518 patients from 40 European countries.

Background: The travel distance from home to a treatment centre, which may impact the stage at diagnosis, has not been investigated for retinoblastoma, the most common childhood eye cancer. We aimed to investigate the travel burden and its impact on clinical presentation in a large sample of patients with retinoblastoma from Africa and Europe.

Methods: A cross-sectional analysis including 518 treatment-naïve patients with retinoblastoma residing in 40 European countries and 1024 treatment-naïve patients with retinoblastoma residing in 43 African countries.

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.

Background: Darolutamide is a structurally distinct androgen-receptor inhibitor that is approved for the treatment of nonmetastatic, castration-resistant prostate cancer. In the planned primary analysis of a phase 3 trial, the median metastasis-free survival was significantly longer with darolutamide (40.4 months) than with placebo (18.

Population preferences for breast cancer screening policies: Discrete choice experiment in Belarus.

Background: Reaching an acceptable participation rate in screening programs is challenging. With the objective of supporting the Belarus government to implement mammography screening as a single intervention, we analyse the main determinants of breast cancer screening participation.

Methods: We developed a discrete choice experiment using a mixed research approach, comprising a literature review, in-depth interviews with key informants (n = 23), "think aloud" pilots (n = 10) and quantitative measurement of stated preferences for a representative sample of Belarus women (n = 428, 89% response rate).

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.

Background: Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. We evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer.

Methods: We conducted a randomized, double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic, castration-resistant prostate cancer and a prostate-specific antigen doubling time of 10 months or less.

BER gene polymorphisms associated with key molecular events in bladder cancer.

Aim: Base excision repair (BER) gene polymorphisms are known to play an independent role in predisposition to developing different cancers as well as to be associated with clinicopathological traits of the disease modifying its clinical outcomes. One of the underlying mechanisms is presumed to include interplay between BER gene polymorphisms and key mutational, epigenetic and chromosomal events in tumor tissues. The present study was aimed at elucidating potential gene-gene interaction and assessing their mutual effects in bladder cancer (BC).

Quality of radiotherapy services in post-Soviet countries: An IAEA survey.

Background: The quality of radiotherapy services in post-Soviet countries has not yet been studied following a formal methodology. The IAEA conducted a survey using two sets of validated radiation oncology quality indicators (ROIs).

Methods: Eleven post-Soviet countries were assessed.

Multiple-field interstitial photodynamic therapy of subcutaneously transplanted cholangiocellular carcinoma RS-1 in rats.

Unlabelled: The aim of present study was to investigate an antitumor efficacy of multiple-field interstitial photodynamic therapy (iPDT) in vivo.

Materials And Methods: The study was performed on 15 white random-bred rats with subcutaneously transplanted cholangiocellular carcinoma RS-1. Chlorine-based photosensitizer (PS) Ce6CPPPS was administered via single injection at a dose of 2.

Response monitoring in follicular lymphoma by synchronous evaluation of minimal residual disease and diffusion-weighted MRI.

Aim: To demonstrate quantitative assessment of tumor response to treatment in patients with follicular lymphoma using parallel monitoring of minimal residual disease (MRD) and diffusion-weighted MRI (MRI-DWI) derived apparent diffusion coefficient (ADC).

Materials And Methods: Two patients with follicular lymphoma were undergone synchronous evaluation of MRD and MRI-DWI at definite time points before, during and after chemotherapy. MRD level was calculated in diagnostic and follow up samples relative to the highest level of amplification of the target.

FGFR3 and TP53 mutations in a prospective cohort of Belarusian bladder cancer patients.

Aim: The aim of this study was to determine the frequencies of FGFR3 and TP53 mutations in a prospective cohort of 150 bladder cancer patients and to assess the relationship between their mutational status and clinicopathological variables.

Materials And Methods: The FGFR3 and TP53 mutations were detected by the SNaPshot method and PCR-single-strand conformational polymorphism analysis followed by DNA sequencing.

Results: The activating FGFR3 mutations were found in 71 (47.

Fluorescent diagnosis and photodynamic therapy for C6 glioma in combination with antiangiogenic therapy in subcutaneous and intracranial tumor models.

Objective: Investigating the distinctions pharmacokinetics of chlorin e6 conjugated with polyvinyl pyrrolidone photosensitizer (Ce6CPPPS)in healthy and tumor tissues of rat brain and evaluating the antitumor efficacy of combination treatment for C6 rat glioma including photodynamic (PDT) and antiangiogenic therapy (AAT).

Materials And Methods: The study was performed on 50 white random-bred rats in subcutaneous and intracranial models of C6 glioma. Photosensitizer (PS) Ce6CPPPS single injection at a dose of 2.

Effects of combined sonodynamic and photodynamic therapies with photolon on a glioma C6 tumor model.

Unlabelled: The aim of this study was to investigate the low-power density sonication, sonodynamic therapy (SDT) with Photolon and combination of SDT and photodynamic therapy (PDT) with Photolon for the ablation of glioma C6 tumor model in rats.

Methods: The study was performed on 50 rats bearing glioma C6. The tumors were sonicated with/without prior intravenous injection of photosensitizer (PS) Photolon (2.

Photolon enhancement of ultrasound cytotoxicity.

Objective: To evaluate the impact of Photolon on cytostatic and cytotoxic effects of therapeutic range ultrasound in C6 glioma cells.

Methods: C6 glioma cells in suspension or monolayer cell culture were exposed to ultrasound (880 kHz, 0.2-0.

The effect of cytostatics and hyperthermia on RAJI human lymphoma cells.

Aim: To evaluate the effect of hyperthermia on cytostatic activity of chemotherapeutic drugs carboplatin, cisplatin, oxaliplatin, carmustine, gemcitabine and etoposide in human lymphoma cell culture.

Methods: RAJI human lymphoma cells were incubated with cytostatics at 37 °C or 42 °C and evaluated for cell culture growth.

Results: The number of viable cells after incubation with the drugs (except for gemcitabine) at 42 °C for 30 min was significantly lower than at 37 °C.

Diffusion-weighted magnetic resonance imaging in non-invasive monitoring of antiangiogenic therapy in experimental tumor model.

Aim: To show usefulness of diffusion-weighted magnetic resonance imaging (MRI) for non-invasive assessment of experimental tumor after antiangiogenic treatment.

Methods: M1 sarcoma was implanted to the peritoneal cavity of the rat and allowed to grow to a palpable tumor size. Animal was treated with a single injection of endothelial growth factor antibody Bevacizumab (Avastin).

Experimental study of antiangiogenic and photodynamic therapies combination for treatment of peritoneal carcinomatosis: preliminary results.

Aim: To create adequate orthotopic model of peritoneal carcinomatosis in rats using a transplantable rat tumor M-1 sarcoma, to assess the early tumor response after intraperitoneal photodynamic and/or antiangiogenic therapy for peritoneal carcinomatosis.

Methods: In 14-18 days after intraperitoneal inoculation, eighteen tumor-bearing animals were divided into three groups and undergone intraperitoneal photodynamic therapy and/or antiangiogenic therapy. Assessment of the tumor posttreatment changes was performed using a method of vital staining with Evans blue, MRI-monitoring and morphologic investigation.